Activation of the mammalian target of rapamycin signalling pathway in epidermal tumours and its correlation with cyclin-dependent kinase 2

British Journal of Dermatology

Volumn 160, Issue 2, 2009, Pages 442-445

  Chen, S J ^a,b   Nakahara, T ^a   Takahara, M ^a   Kido, M ^a   Dugu, L ^a   Uchi, H ^a   Takeuchi, S ^a   Tu, Y T ^b   Moroi, Y ^a   Furue, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

AKT; Cyclin dependent kinase 2; Epidermal tumour; Mammalian target of rapamycin

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN S6;

ACTINIC KERATOSIS; ARTICLE; BOWEN DISEASE; IMMUNOHISTOLOGY; KERATOACANTHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEBORRHEIC KERATOSIS; SKIN TUMOR; SQUAMOUS CELL CARCINOMA;

BOWEN'S DISEASE; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE 2; EPIDERMIS; HUMANS; KERATOSIS, ACTINIC; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; SKIN NEOPLASMS;

EID: 58349122896     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08903.x     Document Type: Article

References (15)

1. Bjornsti M, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004 4 : 335 8.
2. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 2004 16 : 564 75.
3. Takano A, Usui I, Haruta T et al. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol 2001 21 : 5050 62.
4. Panigrahi AR, Pinder SE, Chan SY et al. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 2004 204 : 93 100.
5. Dufner A, Thomas J. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 1999 253 : 100 9.
6. Sarbassov DD, Sabatini DM. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem 2005 280 : 39505 9.
7. Petroulakis E, Mamane Y, Bacquer OL et al. mTOR: implications for cancer and anticancer therapy. Br J Cancer 2006 94 : 195 9.
8. Colozza M, Azambuja E, Cardoso F et al. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005 16 : 1723 39.
9. Kuhling H, Alm P, Olsson H et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 2003 199 : 424 31.
10. Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004 9 : 95 104.
11. Lee M-H, Yang H-Y. Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metast Rev 2003 22 : 435 49.
12. Liu H, Moroi Y, Yasumoto S et al. Expression of insulin-like growth factor-1 receptor, p-AKT and p-ERK1/2 protein in extramammary Paget's disease. Br J Dermatol 2006 155 : 586 91.
13. Tee AR, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 2005 16 : 29 37.
14. Maddika S, Ande SR, Wiechec E et al. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J Cell Sci 2008 121 : 979 88.
15. Kim SJ, Nakayama S, Miyoshi Y et al. Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol 2008 19 : 68 72.